论文部分内容阅读
目的观察阿托伐他汀对糖尿病肾病(DN)患者的肾脏的保护作用。方法将86例DN患者随机分为两组,两组患者均给予糖尿病饮食、控制血糖和降血压等常规治疗,对照组给予贝那普利,观察组在对照组治疗的基础上给予阿托伐他汀,两组疗程均为12周。于治疗前和治疗12周后检测两组尿微量白蛋白排泄率(UAER)、血肌酐(Scr)、低密度脂蛋白胆固醇(LDL-C)、总胆固醇(TC)、甘油三酯(TG)、空腹血糖(FPG)、糖化血红蛋白(HbA1c)。结果治疗后与治疗前比较,对照组UAER、TC、FBG、HbA1c显著降低(P<0.05),治疗组UAER、Scr、LDL-C、TC、TG、FBG、HbA1c显著降低(P<0.05);两组治疗后比较,治疗组UAER、Scr、TC、TG显著低于对照组(P<0.05)。结论阿托伐他汀可以减少蛋白尿,延缓肾功能的恶化。
Objective To observe the protective effects of atorvastatin on the kidney of patients with diabetic nephropathy (DN). Methods Eighty-six patients with DN were randomly divided into two groups. Patients in both groups were given routine therapy such as diabetic diet, blood sugar control and blood pressure lowering. The control group was given benazepril. The observation group was given atorvastatin Statin, two groups of treatment are 12 weeks. The levels of urinary albumin excretion (UAER), serum creatinine (Scr), low density lipoprotein cholesterol (LDL-C), total cholesterol (TC) and triglyceride (TG) were measured before treatment and 12 weeks after treatment. , Fasting blood glucose (FPG), glycated hemoglobin (HbA1c). Results After treatment, the levels of UAER, TC, FBG and HbA1c in the control group were significantly decreased (P <0.05). The levels of UAER, Scr, LDL - C, TC, TG, FBG and HbA1c in the control group were significantly decreased (P <0.05) After treatment, UAER, Scr, TC, TG in the treatment group were significantly lower than those in the control group (P <0.05). Conclusions Atorvastatin can reduce proteinuria and delay the deterioration of renal function.